Showing 18 of 18 recruiting trials for “Classic Hodgkin lymphoma”
PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
👨⚕️ Evgeny E Zvonkov, MD, PhD, National Medical Research Center for Hematology📍 1 site📅 Started Jul 2025View details ↗
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
👨⚕️ Andrey Kaprin, FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation📍 1 site📅 Started Apr 2025View details ↗
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
👨⚕️ Ryan Lynch, MD, Fred Hutch/University of Washington Cancer Consortium📍 5 sites📅 Started Mar 2025View details ↗
A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL
👨⚕️ Natalia Mikhailova, MD, PhD, St. Petersburg State Pavlov Medical University📍 1 site📅 Started Oct 2024View details ↗
PD-1 Inhibitors Maintenance for cHL Post-autoHCT
👨⚕️ Natalia Mikhailova, MD, St. Petersburg State Pavlov Medical University📍 3 sites📅 Started Sep 2024View details ↗
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
RecruitingNCT05705531 ↗
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
👨⚕️ David A Bond, MD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started Jun 2023View details ↗
Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
👨⚕️ Kristie Blum, MD, Emory University Hospital/Winship Cancer Institute📍 2 sites📅 Started May 2022View details ↗
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →